ArticlePharmaceuticals (Basel, Switzerland)2017
The Beginning and Development of the Theranostic Approach in Nuclear Medicine, as Exemplified by the Radionuclide Pair
Article in Pharmaceuticals (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed.
- Article
- Establishing Pb-203 production from electrodeposited Tl targets at Brookhaven National Laboratory.EJNMMI radiopharmacy and chemistry · 2025Article
- Radiotheranostic landscape: A review of clinical and preclinical development.European journal of nuclear medicine and molecular imaging · 2025Review
- Radionuclide-Dependent Stimulation of Antitumor Immunity in GD2-Targeted Radiopharmaceutical Therapy Combined with Immune Checkpoint Inhibitors.Radiation (Multidisciplinary Digital Publishing Institute) · 2025Article
- Monovalent and Divalent Designs of Copper Radiotheranostics Targeting Fibroblast Activation Protein in Cancer.Cancers · 2024Article
- Trop2-Targeted Molecular Imaging in Solid Tumors: Current Advances and Future Outlook.Molecular pharmaceutics · 2024Review
- Quantitative SPECT imaging ofEJNMMI physics · 2024Article
- Excitation functions ofScientific reports · 2024Article
- Review
- Terbium-149 production: a focus on yield and quality improvement towards preclinical application.Scientific reports · 2024Article
- Aspects and prospects of preclinical theranostic radiopharmaceutical development.Theranostics · 2024Review
- Medicinal (Radio) Chemistry: Building Radiopharmaceuticals for the Future.Current medicinal chemistry · 2024Review
- Separation of cyclotron-produced cobalt-55/58m from iron targets using cation exchange chromatography with non-aqueous solvents and extraction chromatography.Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine · 2023Article
- Siderocalin fusion proteins enable a newRSC chemical biology · 2023Article
- Preclinical Evaluation of a Companion Diagnostic Radiopharmaceutical, [Molecular pharmaceutics · 2023Article
- Copper radionuclides for theranostic applications: towards standardisation of their nuclear data. A mini-review.Frontiers in chemistry · 2023Review
- Cellular lethal damage ofFrontiers in medicine · 2023Article
- Cells and material-based strategies for regenerative endodontics.Bioactive materials · 2022Review
- Evaluation of the Effect of Macrocyclic Ring Size on [Inorganic chemistry · 2022Article
- Porphyrins as Chelating Agents for Molecular Imaging in Nuclear Medicine.Molecules (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the context of radiopharmacy and molecular imaging, the concept of theranostics entails a therapy-accompanying diagnosis with the aim of a patient-specific treatment. Using the adequate diagnostic radiopharmaceutical, the disease and the state of the disease are verified for an individual patient. The other way around, it verifies that the radiopharmaceutical in hand represents a target-specific and selective molecule: the "best one" for that individual patient. Transforming diagnostic imaging into quantitative dosimetric information, the optimum radioactivity (expressed in maximum radiation dose to the target tissue and tolerable dose to healthy organs) of the adequate radiotherapeutical is applied to that individual patient. This theranostic approach in nuclear medicine is traced back to the first use of the radionuclide pair
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.